Nantahala Capital Management LLC Invests $1.30 Billion in VYNE Therapeutics Inc. $VYNE

Nantahala Capital Management LLC purchased a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,000,000 shares of the company’s stock, valued at approximately $1,301,400,000. Nantahala Capital Management LLC owned approximately 298.51% of VYNE Therapeutics as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of VYNE Therapeutics during the 2nd quarter worth approximately $29,000. XTX Topco Ltd acquired a new position in shares of VYNE Therapeutics in the 4th quarter valued at $46,000. GSA Capital Partners LLP purchased a new position in shares of VYNE Therapeutics in the 2nd quarter valued at $47,000. Rangeley Capital LLC grew its position in shares of VYNE Therapeutics by 18.1% in the 1st quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after buying an additional 18,064 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in VYNE Therapeutics during the 3rd quarter worth $74,000. 83.78% of the stock is currently owned by hedge funds and other institutional investors.

VYNE Therapeutics Stock Performance

Shares of VYNE opened at $28.32 on Friday. VYNE Therapeutics Inc. has a fifty-two week low of $14.03 and a fifty-two week high of $79.75. The company has a market capitalization of $18.98 million, a price-to-earnings ratio of -74.54 and a beta of 2.00. The firm has a 50-day simple moving average of $31.74 and a 200-day simple moving average of $31.45.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($3.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($3.33). The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

VYNE Therapeutics Announces Dividend

The company also recently disclosed a special dividend, which was paid on Thursday, July 23rd. Investors of record on Wednesday, July 22nd were issued a dividend of $19.00 per share.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.